US HUPO 2022 features a full program of outstanding plenary speakers, a great variety of 14 parallel scientific sessions and oral presentations, as well as educational short courses and topic-specific evening workshops. Read More
Join Seer at Palm Springs in person, or virtually March 27-30 for the Association of Biomolecular Resource Facilities (ABRF) Annual Meeting. Be sure to attend our three poster sessions/flash talks and chat with the authors about the data. During meeting breaks, stop by our booth with any questions you have […] Read More
ASMS is the largest gathering of mass spectrometry scientists in the world, and we are pleased to be joining you! We want to learn more about your research discoveries and needs and share with you how Seer’s automated, unbiased proteomics platform and proprietary nanoparticles enable deep, rapid proteomics studies at […] Read More
The General Meeting is AGBT’s flagship event for bringing together global leaders, researchers, and innovators. Read More
The International Mass Spectrometry Conference Annual General Meeting is the central event in the IMSC calendar, drawing together colleagues from member universities for research workshops, policy discussions and business meetings to further advance the Network. Read More
The ASHG 2022 Annual Meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. It will be held in Los Angeles, California from Tuesday, October 25 through Saturday, October 29 and is expected to be an amazing event for Genetics and Genomics. Read More
Founded in 2001, HUPO turned 20 in 2021! We are celebrating 20 years of excellent scientific conferences, community engagement, science advocacy, and advanced education! The annual HUPO world congress has been a key event for proteomics scientists since 2002 and has continued through the recent pandemic challenges. HUPO community-centric projects, […] Read More
Title goes here
Philip Ma is the Chief Business Officer for Seer. Previously, he was Vice-President for Digital Health Technologies and Data Sciences at Biogen, a group that he established in 2015 to discover insights and create value for Biogen and its patients. Prior to joining Biogen, Philip was Senior Partner at McKinsey & Company, where he served global leaders in the pharmaceutical and biotech sectors, leading the West Coast Healthcare Practice and global Personalized Medicine practice for the Firm. Active in community affairs, Philip also serves on the Board of Committee of 100, a group of Chinese-American business and community leaders focused on U.S. China relations and the Asian-American experience. Before McKinsey, Philip was a macromolecular crystallographer in the lab of Dr. Carl O. Pabo at Massachusetts Institute of Technology, where he received his Ph.D. in Biology. Philip also has degrees in Biochemistry (A.B. from Harvard College) and in Economics (MPhil from Oxford University, where he was a Rhodes Scholar).